| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
The specific molecular targets of Ophiopogonin C are not fully characterized in the available literature. As a steroidal glycoside from Ophiopogon japonicus, it is known to exhibit cytotoxic activity against human tumor cell lines. The compound has also been investigated for its role in improving myocardial function, reducing oxidative stress, and modulating immune responses. Steroidal saponins from Ophiopogon species are known to interact with various cellular targets including membrane receptors, ion channels, and signaling pathways involved in cell proliferation, apoptosis, and inflammation. However, the precise molecular targets of Ophiopogonin C remain to be fully elucidated through systematic target identification studies.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Ophiopogonin C exhibits cytotoxic activity against two human tumor cell lines: MG-63 (osteosarcoma) and SNU387 (hepatocellular carcinoma), with IC50 values of 19.76 microM and 15.51 microM, respectively. These findings indicate that Ophiopogonin C has moderate cytotoxic activity against cancer cells. The compound is also being investigated for its potential to improve myocardial function, reduce oxidative stress, and modulate immune responses. However, detailed in vitro mechanistic studies, including the compound's effects on cell signaling pathways, apoptosis, and cell cycle progression, are limited. Further research is needed to fully characterize the in vitro biological activities of this compound.
|
| ln Vivo |
In vivo studies on Ophiopogonin C are limited. As a natural product from Ophiopogon japonicus, which has a long history of traditional use for heart health and as a general tonic, the compound is presumed to contribute to the pharmacological effects of the crude herb. Ophiopogon japonicus has been used traditionally for its cardioprotective, immunomodulatory, and anti-inflammatory properties. However, specific in vivo studies on Ophiopogonin C are not widely documented in the available literature. The compound's potential therapeutic applications in cardiovascular disease, cancer, and immune disorders warrant further investigation using appropriate animal models.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assays for Ophiopogonin C are not well-documented in the available literature. As a steroidal glycoside, the compound's interactions with potential molecular targets could be studied using standard biochemical techniques. These might include radioligand binding assays for receptor targets, enzyme activity assays for enzymatic targets, and surface plasmon resonance or isothermal titration calorimetry for binding affinity measurements. However, specific protocols for studying Ophiopogonin C have not been published. For researchers interested in studying this compound, protocols would need to be developed based on the known activities of related steroidal saponins from Ophiopogon species.
|
| Cell Assay |
Cellular assays for Ophiopogonin C have been conducted using human tumor cell lines including MG-63 (osteosarcoma) and SNU387 (hepatocellular carcinoma). Cells are cultured in appropriate media and treated with varying concentrations of the compound for 48-72 hours. Cell viability is assessed using standard assays such as MTT or CCK-8. The IC50 values are calculated by fitting the dose-response data to a sigmoidal curve. For mechanistic studies, additional assays can be performed to assess apoptosis (e.g., Annexin V staining, caspase activity), cell cycle distribution (flow cytometry), and signaling pathway activation (Western blotting). These assays help to elucidate the compound's mechanism of cytotoxic action.
|
| Animal Protocol |
In vivo animal studies for Ophiopogonin C are not well-documented in the available literature. For similar steroidal saponins from Ophiopogon japonicus, typical in vivo protocols might involve the use of mouse models of myocardial ischemia, cancer xenograft models, or models of oxidative stress and inflammation. The compound would typically be administered orally or intraperitoneally at various doses, and efficacy would be assessed by measuring biochemical markers, tissue histopathology, and functional outcomes. However, specific experimental protocols for Ophiopogonin C have not been published. Further research is needed to establish the in vivo pharmacological profile of this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Ophiopogonin C are not available in the current literature. As a steroidal glycoside with a high molecular weight (915.07) and complex structure, the compound would be expected to have limited oral bioavailability and undergo metabolic transformation. The compound is typically stored as powder at -20degC for up to 3 years or at 4degC for up to 2 years. Solubility information is limited, but Ophiopogonin C may dissolve in DMSO. Detailed pharmacokinetic parameters such as half-life, clearance, bioavailability, and tissue distribution have not been determined for this compound. Further pharmacokinetic studies are needed to support any potential therapeutic applications.
|
| Toxicity/Toxicokinetics |
Toxicological data for Ophiopogonin C are not available in the published literature. As a natural product from Ophiopogon japonicus, which has a long history of traditional medicinal use, the compound is presumed to have a reasonable safety profile. Ophiopogon japonicus has been consumed as a medicinal herb with no major safety concerns reported. However, the specific toxicity profile of purified Ophiopogonin C has not been systematically evaluated in preclinical studies. Standard toxicological assessments, including acute toxicity, repeat-dose toxicity, and genotoxicity studies, would be needed to establish the safety profile of this compound for any potential therapeutic applications.
|
| References | |
| Additional Infomation |
Ophiopogonin C is a research-grade natural product isolated from the tubers of Ophiopogon japonicus (Mai Men Dong), a traditional Chinese medicinal herb. It is a rare C29 steroidal glycoside with a molecular formula of C46H74O18 and molecular weight of 915.07. The compound has demonstrated cytotoxic activity against human tumor cell lines MG-63 and SNU387 and is being investigated for potential cardioprotective, antioxidant, and immunomodulatory effects. Ophiopogon japonicus is a well-known herb in traditional Chinese medicine, and its steroidal saponins are studied for various pharmacological activities. The compound is not approved for clinical use and is available only for research purposes.
|
| Molecular Formula |
C46H72O17
|
|---|---|
| Molecular Weight |
897.0537
|
| Exact Mass |
914.487
|
| CAS # |
65586-25-6
|
| PubChem CID |
138911419
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
64
|
| Complexity |
1620
|
| Defined Atom Stereocenter Count |
26
|
| SMILES |
C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5([C@@H](C[C@@H](C6)O)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)C)O)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)C)OC1.CC(=O)O
|
| InChi Key |
FUVOCASXULVHFF-VFOULCERSA-N
|
| InChi Code |
InChI=1S/C44H70O16.C2H4O2/c1-18-9-12-44(54-16-18)19(2)30-28(60-44)15-26-24-8-7-22-13-23(45)14-29(43(22,6)25(24)10-11-42(26,30)5)57-41-38(59-40-36(52)34(50)31(47)20(3)55-40)37(32(48)21(4)56-41)58-39-35(51)33(49)27(46)17-53-39;1-2(3)4/h7,18-21,23-41,45-52H,8-17H2,1-6H3;1H3,(H,3,4)/t18-,19+,20+,21-,23-,24-,25+,26+,27-,28+,29-,30+,31+,32+,33+,34-,35-,36-,37+,38-,39+,40+,41+,42+,43+,44-;/m1./s1
|
| Chemical Name |
acetic acid;(2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-5-hydroxy-2-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,14R,16R)-16-hydroxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-14-yl]oxy-6-methyl-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1148 mL | 5.5738 mL | 11.1477 mL | |
| 5 mM | 0.2230 mL | 1.1148 mL | 2.2295 mL | |
| 10 mM | 0.1115 mL | 0.5574 mL | 1.1148 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
